See more : GACM Technologies Limited (GATECH.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Pharmala Biotech Holdings Inc. (MDMA.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmala Biotech Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nanfang Black Sesame Group Co., Ltd. (000716.SZ) Income Statement Analysis – Financial Results
- Kering SA (PPRUY) Income Statement Analysis – Financial Results
- WPIL Limited (WPIL.BO) Income Statement Analysis – Financial Results
- Tingo, Inc. (IWBB) Income Statement Analysis – Financial Results
- Nuvectis Pharma, Inc. (NVCT) Income Statement Analysis – Financial Results
Pharmala Biotech Holdings Inc. (MDMA.CN)
About Pharmala Biotech Holdings Inc.
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 532.00K | 78.07K | 0.00 |
| Cost of Revenue | 77.90K | 2.29K | 303.00 |
| Gross Profit | 454.10K | 75.78K | -303.00 |
| Gross Profit Ratio | 85.36% | 97.07% | 0.00% |
| Research & Development | -166.52K | 0.00 | 0.00 |
| General & Administrative | 1.15M | 1.05M | 2.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 1.15M | 1.05M | 2.51M |
| Other Expenses | 231.47K | 0.00 | 0.00 |
| Operating Expenses | 1.22M | 1.06M | 2.51M |
| Cost & Expenses | 1.31M | 1.06M | 2.51M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 52.77K | 12.14K | 303.00 |
| EBITDA | -710.19K | -973.45K | -2.51M |
| EBITDA Ratio | -133.49% | -1,246.89% | 0.00% |
| Operating Income | -762.95K | -985.58K | -2.51M |
| Operating Income Ratio | -143.41% | -1,262.43% | 0.00% |
| Total Other Income/Expenses | -16.86K | 0.00 | 0.00 |
| Income Before Tax | -779.81K | -985.58K | -2.51M |
| Income Before Tax Ratio | -146.58% | -1,262.43% | 0.00% |
| Income Tax Expense | 0.00 | -3.00 | -2.08M |
| Net Income | -779.81K | -985.58K | -2.51M |
| Net Income Ratio | -146.58% | -1,262.43% | 0.00% |
| EPS | -0.01 | -0.01 | -0.03 |
| EPS Diluted | -0.01 | -0.01 | -0.03 |
| Weighted Avg Shares Out | 84.53M | 83.00M | 83.00M |
| Weighted Avg Shares Out (Dil) | 84.53M | 83.00M | 83.00M |
Source: https://incomestatements.info
Category: Stock Reports